2nd Annual Bio/Pharmaceutical Cold Chain China 2012 – the ONLY conference addressing the cold chain issues faced by the pharmaceutical industry in China
Today's global biopharma cold-chain market is $5.1 billion, growing to $6.6 billion by 2011…Based on projected market growth rates; seven of the top 10 global pharma products in 2014 will require cold-chain handling.Nick Basta,Editor in chief of Pharmaceutical Commerce, Co-author of Cold Chain Biopharma,Logistics Sourcebook 2010
Many multinational pharmaceutical companies have set up operations and manufacturing plants in China and we are seeing an increasing number of clinical trials are being conducted within the country.
With this in mind, however, China is still far from developing a comprehensive and efficient cold chain distribution system for pharmaceutical products. The large land mass, the extreme weather conditions across varied terrains and an inefficient transportation system across multi-tiered cities and rural areas means cold chain management is a huge challenge for the pharmaceutical industry in China.
Both global and local transport of temperature-sensitive investigational drugs and clinical materials presents a tremendous challenge for pharmaceutical and biotechnology companies in China. With the overwhelming complexity of assuring product integrity throughout the entire distribution chain, the increased scrutiny placed on in-transit temperature control and monitoring and huge costs that can be potentially incurred due to temperature excursions, it is more important than ever to get it right the first time.
The 2nd Annual Bio/Pharmaceutical Cold Chain China 2012 is THE ONLY gathering of its kind in China providing the largest and most comprehensive forum for pharmaceutical, biotech and medical device professionals in China involved in the temperature-controlled supply chain. Attendees will be able to network with and learn from other organisations who face similar challenges in monitoring, controlling, and maintaining temperatures of products throughout the supply chain – from manufacturing, warehousing, wholesalers, pharmacies, hospitals, and ultimately to the end users.
What’s New in 2012?
- Presents two annual events - 3rd Annual Clinical Trial Supply China and 2nd Annual Bio/Pharma Cold Chain China that features content and case-studies that address the unique supply chain needs in China pharmaceutical industry.
- Regulatory updates from Chinese regulators including SFDA, Ministry of Health, Custom, Ministry of Science and Technology on distribution of temperature controlled product and clinical trials supply materials
- International regulatory perspective from US FDA and MHRA on new global updates
- Meet and network with more than 200+ key stakeholders in the China bio/pharma supply chain industry
- 15 rountable discussions topics participate to overcome your day to day supply chain challenges
- FIRST and ONLY supply chain Award for pharmaceutical industry in China
Key themes for 2nd Annual Bio/Pharmaceutical Cold Chain China 2012:
- The latest updates from Chinese regulatory authorities on pharmaceutical cold chain management regulations and guidelines
- Exploring strategies to balance international cold chain requirements and local practices faced by global pharmaceutical companies in China
- Achieving cost efficiency in cold chain operations
- Identifying best practices to manage and strengthen relations with 3PL providers to ensure product integrity and on-time delivery
- Understanding how 3PLs manage their cold chain operations in China
- Assessing new technologies, innovations and solutions available in the market to ensure optimal end-to-end cold chain management
Cold chain China is in need of more sophisticated attention and global participation to better understand new methods and actions to improve cold chain shipping and distribution.VP, Global Sales & Marketing, Active CC Boxes
Cold chain is one of the key points/process to ensure drug product quality.Director, QA/QC, Novartis
Thanks to the conference organiser’s contribution to set up a communication channel. Good and smooth meetingStudy Drug Coordinator, Astrazeneca Pharmaceutical
A good platform for networking and knowledge sharing. A wide range of topics were presented and provided good insight of cold chain operations.Business Development & Strategy Manager, DHL
This event looked at practical solution developments for an extremely challenging market. Very down to earth and realistic.Head, Strategic Innovation, LifeConEx